NCT04411667View on ClinicalTrials.gov

Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

PHASE4CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

June 23, 2020

Study Completion Date

June 23, 2020

Conditions

Sars-CoV2

Interventions

DRUG

Octagam

Standard of Care plus Octagam infusion for 3 days.

Trial Locations (2)

91942

Sharp Grossmont Hospital, La Mesa

92123

Sharp Memorial Hospital, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Octapharma

INDUSTRY

lead

George Sakoulas, MD

OTHER

NCT04411667 - Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19 | Biotech Hunter | Biotech Hunter